Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-POPF: Extended Antibiotics After Pancreatoduodenectomy
NCT05753735Phase 2Terminated
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jan 2024
- Primary completion
- Mar 2024
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of piperacillin + tazobactam, amoxicillin + clavulanate in pancreatic fistula (POPF), sponsored by Case Comprehensive Cancer Center. Started Jan 2024; status: terminated.
02
Drugs
piperacillin + tazobactamamoxicillin + clavulanate
03
Conditions
pancreatic fistula (POPF)
Beyond the preview
Go deeper on NCT05753735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753735.